TrialThe oncologist2022

Rh-Endostatin Plus Irinotecan/Cisplatin as Second-Line Therapy for Advanced Esophageal Squamous Cell Carcinoma: An Open-Label, Phase II Study.

Zhihuang Hu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.